Cargando…

Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region

BACKGROUND: Zika virus (ZIKV) has become a global threat with immediate need for accurate diagnostics, efficacious vaccines and therapeutics. Several ZIKV envelope (Env)-based vaccines have been developed recently. However, many commercially available ZIKV Env are based on the African lineage and pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Young Chan, Lopez-Camacho, Cesar, Nettleship, Joanne E., Rahman, Nahid, Hill, Michelle L., Silva-Reyes, Laura, Ortiz-Martinez, Georgina, Figueroa-Aguilar, Gloria, Mar, María Antonieta, Vivanco-Cid, Héctor, Rollier, Christine S., Zitzmann, Nicole, Viveros-Sandoval, Martha Eva, Owens, Raymond J., Reyes-Sandoval, Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307127/
https://www.ncbi.nlm.nih.gov/pubmed/30587198
http://dx.doi.org/10.1186/s12985-018-1104-6
_version_ 1783382934577741824
author Kim, Young Chan
Lopez-Camacho, Cesar
Nettleship, Joanne E.
Rahman, Nahid
Hill, Michelle L.
Silva-Reyes, Laura
Ortiz-Martinez, Georgina
Figueroa-Aguilar, Gloria
Mar, María Antonieta
Vivanco-Cid, Héctor
Rollier, Christine S.
Zitzmann, Nicole
Viveros-Sandoval, Martha Eva
Owens, Raymond J.
Reyes-Sandoval, Arturo
author_facet Kim, Young Chan
Lopez-Camacho, Cesar
Nettleship, Joanne E.
Rahman, Nahid
Hill, Michelle L.
Silva-Reyes, Laura
Ortiz-Martinez, Georgina
Figueroa-Aguilar, Gloria
Mar, María Antonieta
Vivanco-Cid, Héctor
Rollier, Christine S.
Zitzmann, Nicole
Viveros-Sandoval, Martha Eva
Owens, Raymond J.
Reyes-Sandoval, Arturo
author_sort Kim, Young Chan
collection PubMed
description BACKGROUND: Zika virus (ZIKV) has become a global threat with immediate need for accurate diagnostics, efficacious vaccines and therapeutics. Several ZIKV envelope (Env)-based vaccines have been developed recently. However, many commercially available ZIKV Env are based on the African lineage and produced in insect cells. Here, we sought to produce Asian-lineage ZIKV Env in mammalian cells for research and clinical applications. METHODS: We designed various gene expression constructs to optimize the production of ZIKV using prM-Env and full or C-terminal truncations of Env; with or without a rat CD4 fusion partner to allow large-scale production of soluble protein in mammalian HEK293 cells. Protein expression was verified by mass spectrometry and western-blot with a pan-flavivirus antibody, a ZIKV Env monoclonal antibody and with immune sera from adenoviral (ChAdOx1) ZIKV Env-vaccinated mice. The resulting Env-CD4 was used as a coating reagent for immunoassay (ELISA) using both mouse and human seropositive sera. RESULTS: Replacement of the C-terminus transmembrane Env domain by a rat CD4 and addition of prM supported optimal expression and secretion of Env. Binding between the antigens and the antibodies was similar to binding when using commercially available ZIKV Env reagents. Furthermore, antibodies from ZIKV patients bound ZIKV Env-CD4 in ELISA assays, whereas sera from healthy blood donors yielded minimal OD background. The serological outcomes of this assay correlated also with ZIKV neutralisation capacity in vitro. CONCLUSIONS: Results obtained from this study indicate the potential of the Asian-lineage Zika Env-CD4 and Env proteins in ELISA assays to monitor humoral immune responses in upcoming clinical trials as well as a sero-diagnostic tool in ZIKV infection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12985-018-1104-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6307127
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63071272019-01-02 Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region Kim, Young Chan Lopez-Camacho, Cesar Nettleship, Joanne E. Rahman, Nahid Hill, Michelle L. Silva-Reyes, Laura Ortiz-Martinez, Georgina Figueroa-Aguilar, Gloria Mar, María Antonieta Vivanco-Cid, Héctor Rollier, Christine S. Zitzmann, Nicole Viveros-Sandoval, Martha Eva Owens, Raymond J. Reyes-Sandoval, Arturo Virol J Research BACKGROUND: Zika virus (ZIKV) has become a global threat with immediate need for accurate diagnostics, efficacious vaccines and therapeutics. Several ZIKV envelope (Env)-based vaccines have been developed recently. However, many commercially available ZIKV Env are based on the African lineage and produced in insect cells. Here, we sought to produce Asian-lineage ZIKV Env in mammalian cells for research and clinical applications. METHODS: We designed various gene expression constructs to optimize the production of ZIKV using prM-Env and full or C-terminal truncations of Env; with or without a rat CD4 fusion partner to allow large-scale production of soluble protein in mammalian HEK293 cells. Protein expression was verified by mass spectrometry and western-blot with a pan-flavivirus antibody, a ZIKV Env monoclonal antibody and with immune sera from adenoviral (ChAdOx1) ZIKV Env-vaccinated mice. The resulting Env-CD4 was used as a coating reagent for immunoassay (ELISA) using both mouse and human seropositive sera. RESULTS: Replacement of the C-terminus transmembrane Env domain by a rat CD4 and addition of prM supported optimal expression and secretion of Env. Binding between the antigens and the antibodies was similar to binding when using commercially available ZIKV Env reagents. Furthermore, antibodies from ZIKV patients bound ZIKV Env-CD4 in ELISA assays, whereas sera from healthy blood donors yielded minimal OD background. The serological outcomes of this assay correlated also with ZIKV neutralisation capacity in vitro. CONCLUSIONS: Results obtained from this study indicate the potential of the Asian-lineage Zika Env-CD4 and Env proteins in ELISA assays to monitor humoral immune responses in upcoming clinical trials as well as a sero-diagnostic tool in ZIKV infection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12985-018-1104-6) contains supplementary material, which is available to authorized users. BioMed Central 2018-12-27 /pmc/articles/PMC6307127/ /pubmed/30587198 http://dx.doi.org/10.1186/s12985-018-1104-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Kim, Young Chan
Lopez-Camacho, Cesar
Nettleship, Joanne E.
Rahman, Nahid
Hill, Michelle L.
Silva-Reyes, Laura
Ortiz-Martinez, Georgina
Figueroa-Aguilar, Gloria
Mar, María Antonieta
Vivanco-Cid, Héctor
Rollier, Christine S.
Zitzmann, Nicole
Viveros-Sandoval, Martha Eva
Owens, Raymond J.
Reyes-Sandoval, Arturo
Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region
title Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region
title_full Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region
title_fullStr Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region
title_full_unstemmed Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region
title_short Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region
title_sort optimization of zika virus envelope protein production for elisa and correlation of antibody titers with virus neutralization in mexican patients from an arbovirus endemic region
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307127/
https://www.ncbi.nlm.nih.gov/pubmed/30587198
http://dx.doi.org/10.1186/s12985-018-1104-6
work_keys_str_mv AT kimyoungchan optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT lopezcamachocesar optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT nettleshipjoannee optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT rahmannahid optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT hillmichellel optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT silvareyeslaura optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT ortizmartinezgeorgina optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT figueroaaguilargloria optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT marmariaantonieta optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT vivancocidhector optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT rollierchristines optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT zitzmannnicole optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT viverossandovalmarthaeva optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT owensraymondj optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT reyessandovalarturo optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion